|
已选(0)清除
条数/页： 排序方式： |
| Association between Chinese Medicine Therapy and Survival Outcomes in Postoperative Patients with NSCLC: A Multicenter, Prospective, Cohort Study 期刊论文
CHINESE JOURNAL OF INTEGRATIVE MEDICINE, 2019, 卷号: 25
作者: Wang Xueqian; Zhang Ying; Hou Wei; Wang Yingtian; Zheng Jiabin; Li Jie; Lin Lizhu; Jiang Yilan; Wang Shenyu; Xie Ying; Zhang Hongliang; Shu Qijin; Li Ping; Wang Wei ; You Jianliang; Li Ge; Liu Jie; Fan Huiting; Zhang Meiying; Lin Hongsheng
  收藏 | 浏览/下载：24/0 | 提交时间：2020/10/26
CELL LUNG-CANCER ADJUVANT CHEMOTHERAPY Chinese medicine non-small cell lung cancer postoperative care cohort study disease-free survival |
| Evaluation of menopausal status among breast cancer patients with chemotherapy-induced amenorrhea 期刊论文
CHINESE JOURNAL OF CANCER RESEARCH, 2018, 卷号: 30
-
收藏 | 浏览/下载：37/0 | 提交时间：2020/10/26
ADJUVANT CHEMOTHERAPY AROMATASE INHIBITORS POSTMENOPAUSAL WOMEN OVARIAN-FUNCTION TAMOXIFEN METAANALYSIS PREDICTORS RECOVERY IMPACT RISK Breast neoplasms drug therapy amenorrhea menopause logistic models |
| Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy 期刊论文
Cancer Biology & Medicine, 2018, 卷号: 15
作者: Tian Ye; Sun Changyu; Zhang Limeng; Pan Yuan
收藏 | 浏览/下载：80/0 | 提交时间：2020/12/28
MiRNA-106a NSCLC cisplatin gemcitabine chemotherapy resistant Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations 期刊论文
CHINESE JOURNAL OF CANCER RESEARCH, 2017, 卷号: 29
-
收藏 | 浏览/下载：32/0 | 提交时间：2020/10/26
EGFR MUTATIONS GEFITINIB TREATMENT 1ST-LINE TREATMENT OPEN-LABEL RARE MULTICENTER ERLOTINIB GENE CHEMOTHERAPY EFFICACY Non-small cell lung cancer EGFR uncommon mutation target therapy |
| Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice 期刊论文
JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2017, 卷号: 18
-
收藏 | 浏览/下载：27/0 | 提交时间：2020/10/26
RANDOMIZED PHASE-III NEOADJUVANT CHEMOTHERAPY ENCAPSULATED DOXORUBICIN 1ST-LINE CHEMOTHERAPY PROGNOSTIC MARKER PLUS DOCETAXEL COMBINATION CYCLOPHOSPHAMIDE TRASTUZUMAB PACLITAXEL Liposomal doxorubicin Breast cancer Adjuvant chemotherapy Therapeutic effect Toxic and side effects |
| A pilot phase II study of neoadjuvant triplet chemotherapy regimen in patients with locally advanced resectable colon cancer 期刊论文
CHINESE JOURNAL OF CANCER RESEARCH, 2016, 卷号: 28
-
收藏 | 浏览/下载：29/0 | 提交时间：2020/10/26
METASTATIC COLORECTAL-CANCER 1ST-LINE TREATMENT ADJUVANT CHEMOTHERAPY PATHOLOGICAL RESPONSE LIVER METASTASES STAGE-II OXALIPLATIN FLUOROURACIL LEUCOVORIN IRINOTECAN 5-Fluorouracil colon cancer irinotecan oxaliplatin neoadjuvant chemotherapy |
| Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma 期刊论文
CHINESE JOURNAL OF CANCER, 2016, 卷号: 35
-
收藏 | 浏览/下载：27/0 | 提交时间：2020/10/26
CONCURRENT CHEMORADIOTHERAPY PROGNOSTIC-FACTORS RADIATION-THERAPY NECK-CANCER REIRRADIATION CHEMOTHERAPY SURVIVAL METAANALYSIS RETREATMENT HEAD Recurrence Nasopharyngeal carcinoma Intensity-modulated radiation therapy Concomitant chemoradiotherapy Cisplatin |
| Expert consensus on maintenance treatment for metastatic colorectal cancer in China 期刊论文
CHINESE JOURNAL OF CANCER, 2016, 卷号: 35
-
收藏 | 浏览/下载：22/0 | 提交时间：2020/10/26
BEVACIZUMAB CAPECITABINE THERAPY XELOX CHEMOTHERAPY OXALIPLATIN TRIAL STOP GO Metastatic colorectal cancer Maintenance therapy Consensus |
| A new prognostic histopathologic classification of nasopharyngeal carcinoma 期刊论文
CHINESE JOURNAL OF CANCER, 2016, 卷号: 35
-
收藏 | 浏览/下载：26/0 | 提交时间：2020/10/26
CONCURRENT CISPLATIN-RADIOTHERAPY ADJUVANT CHEMOTHERAPY RANDOMIZED-TRIAL STAGING SYSTEM CANCER CHEMORADIOTHERAPY METAANALYSIS CHINA SURVIVAL UNION Nasopharyngeal carcinoma Pathologic classification Prognosis |
| Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy 期刊论文
CHINESE MEDICAL JOURNAL, 2016, 卷号: 129
-
收藏 | 浏览/下载：26/0 | 提交时间：2020/10/26
PLATINUM-BASED CHEMOTHERAPY CELL LUNG-CANCER III COLON-CANCER THYMIDYLATE SYNTHASE ADJUVANT CHEMOTHERAPY PREDICTIVE-VALUE GASTRIC-CANCER LINK REPAIR ERCC1 EXPRESSION Colorectal Cancer Excision Repair Cross-complementation Group 1 Prognosis |
